AmplatzerTM Septal Occluder; AmplatzerTM Multifenestrated Septal Occluder - Cribriform
ABBOTT MEDICAL · Decision date May 28, 2026
What did the FDA decide?
FDA records P000039/S084 as a supplement to PMA P000039, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 28, 2026.
FDA approval order statement
adding an alternate polyethylene terephthalate (PET) yarn supplier
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- May 28, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P000039/S084
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- MLV
- Decision code
- OK30
- Decision date
- May 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Transcatheter septal occluder.
- Applicant
- Abbott Medical
- Product code
- MLV
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P000039/S083 · Related supplement
Amplatzer Septal Occluder; Amplatzer Multi-Fenestrated Septal Occluder - Cribriform
P000039/S084 received
Application receipt date recorded by FDA.
P000039/S084 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P000039. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P000039
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 23, 2025 | FDA |
Explore the linked device profile
Other records with product code MLV
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | PMA supplement | Aug 3, 2026 | FDA | |
AmplatzerTM Muscular VSD OccluderP040040/S051 | ABBOTT MEDICAL | PMA supplement | May 28, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | May 28, 2026 | FDA | |
GORE CARDIOFORM Septal OccluderP050006/S118 | W. L. Gore & Associates, Inc. | PMA supplement | May 8, 2026 | FDA |
| W. L. Gore & Associates, Inc. | PMA supplement | Feb 20, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 177 County Rd. B E., St. Paul, MN, 55117
Sources and methodology
- Original FDA record: P000039/S084
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

